drugset / Trial / NCT05668962
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).
Timeline
- Start
- 2023-03-01
- Primary completion
- 2025-03-01
- Completion
- 2026-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selpercatinib | Small molecule | — | Oral |
| Background | I131 | Other / unclassified | — | Oral |
| Background | rhTSH | Protein / enzyme biologic | — | — |